Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection

Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.

STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at statnews.com →

More in Health & Medicine

More from Thursday 20 August →